Skip to main content

Table 1 Characteristic of 69 immunocompromised patients

From: Diagnostic value of metagenomic next-generation sequencing of bronchoalveolar lavage fluid for the diagnosis of suspected pneumonia in immunocompromised patients

Characteristic 69 patients
Age (year), mean ± SD 57 ± 15
Gender, male, n (%) 44(64)
Immunocompromised status, n (%)  
 Hematologic malignancy 23(33)
 Solid-organ transplantation 14(20)
 Solid tumour receiving chemotherapy 5(7)
 Immunosuppressive therapya 21(30)
 Prolonged corticosteroid therapyb 33(48)
Disease severity  
 PSI score, mean ± SD 127 ± 51
 Invasive mechanical ventilation, n (%) 22(32)
 Septic shock, n (%) 25(36)
Laboratory findings  
 WBC (109/L), median (Q1, Q3) 6.58(4.93,11.05)
 Neutrophils (109/L), median (Q1, Q3) 5.66(3.23,9.39)
 Lymphocyte count (106/L), median (Q1, Q3) 0.73(0.35,1.17)
 PaO2/FiO2, mean ± SD 196 ± 98
 Albumin (g/L), mean ± SD 30 ± 7
Serum creatinine(mmol/L), median (Q1, Q3) 80(57, 127)
 LDH (U/L), median (Q1, Q3) 432(304, 726)
 CRP (mg/l), median (Q1, Q3) 88(42,149)
 PCT (ng/ml), median (Q1, Q3) 0.27(0.11,1.20)
outcome  
 Total 30-day mortality, n (%) 14(20)
  1. PSI pneumonia severity index, WBC white blood cell, LDH lactate dehydrogenase, CRP C-reactive protein, PCT procalcitonin
  2. aMore than 2 weeks. Underlying diseases include Dermatomyositis (2), Leukemia (1), connective tissue diseases (6), Solid-organ transplantation (9), Hemophilia (1), Chronic nephritic syndrome (1), Thrombocytopenia (1)
  3. bDefined as > 0.3 mg/kg/d of prednisone-equivalent for ≥ 3 weeks. Underlying diseases include Dermatomyositis (1), Connective tissue diseases (9), Solid-organ transplantation (10), Hemophilia (1), Nephrotic syndrome (6), Thrombocytopenia (1), interstitial lung disease (1), Hematologic malignancy (2), Intracranial tumour (1), Dermatology (1)